Avacta Group (AVCT)

 

AVCT Share PerformanceMore

52 week high119.50 08/03/16
52 week low66.30 23/02/17
52 week change -48.50 (-41.81%)
4 week volume271,589 30/01/17

Media for (AVCT)

Presenter: Dr. Alastair Smith
31/07/2014
Presenter: Dr. Alastair Smith
06/05/2014

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Director/PDMR Shareholding

RNS Number: 3868V Avacta Group PLC 30 January 2017 30 January 2017 Avacta Group plc ("Avacta" or "the Group" or "the Company") Director/PDMR Shareholding Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and research reagents, announces the following changes to the equity incentives of its Chief Executive Officer, Alastair Sm...

Result of Annual General Meeting

RNS Number: 7412U Avacta Group PLC 20 January 2017 20 January 2017 Avacta Group plc ("Avacta" or "the Group" or "the Company") Result of Annual General Meeting Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and research reagents, announces that at the Annual General Meeting held earlier today, all resolutions were duly pas...

Avacta sees substantial progress

Avacta Group has made substantial progress in the past year in demonstrating the performance and differentiation of its ...

Trading Update

RNS Number: 6699U Avacta Group PLC 20 January 2017 20 January 2017 Avacta Group plc ("Avacta" or "the Group" or "the Company") AGM business update and notice of results Substantial progress in therapeutic programme Multiple third party technology evaluations ongoing Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and resea...

Avacta CEO to present at London forum

Avacta Group chief executive Alastair Smith will be presenting at the London Growth and Innovation Forum on 31 Janua...

Presenting at London Growth and Innovation Forum

RNS Number: 8476T Avacta Group PLC 11 January 2017 11 th January 2017 Avacta Group plc ("Avacta" or "the Group" or "the Company") Avacta to present at the London Growth and Innovation Forum Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and research reagents, is pleased to announce that its Chief Executive, Alastair Smith, w...

Avacta Plc to present at the Growth and Innovation Forum 2017 in London on 31 January 2017

Avacta Plc to present at the Growth and Innovation Forum 2017 in London on 31 January 2017 Alastair Smith, CEO of Av...

Director Dealing and Issue of Equity

RNS Number: 3746T Avacta Group PLC 05 January 2017 05 January 2017 Avacta Group plc ("Avacta" or "the Group" or "the Company") Director Dealing and Issue of Equity Avacta Group plc (AIM: AVCT), the developer of Affimer biotherapeutics and research reagents, announces that application has been made for 4,340 new ordinary shares of 10p each (the "N...

Fundamental DataMore

EPS-6.86
Dividend yield0 %

Equity Research (AVCT)

hardman & co
Avacta Group Plc
02/11/2016
Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody...
hardman & co
Avacta Group Plc
17/10/2016
Avacta is the proprietary owner of Affimer technology for the development of bio-therapeutics, diagnostic tests and research reagents. Affimers represent a revolutionary alternative to the...
hardman & co
Avacta Group Plc
19/07/2016
Avacta is a life science company providing high quality and highly specific tools to the biopharmaceutical industry to help in the diagnosis and treatment of humans and animals. The group’s Affimer...

Latest discussion posts More

  • Re: Affimer Technology

    I'm also aware Paul Ko Ferrigno has resigned from avacta life sciences ltd (not the plc - he was not a director of avacta group plc) - though have no idea why or impact, if ...
    16-Feb-2017
    mol42
  • Affimer Technology

    Introduction video updated today http://www.avacta.com/ mol
    16-Feb-2017
    mol42
  • Re: Finncap

    Thanks for that Drewster .. but i notice it a lot not only with this share. Others complain it is very misleading i think there is some campaign going on to stop it.
    14-Feb-2017
    Ripley94

Users' HoldingsMore

Users who hold Avacta Group also hold..
LLOYDS GRP.23%
ROCKHOPPER15%
BARCLAYS14%
ROYAL BANK SCOT12%
RENEURON11%

Codes & Symbols

ISINGB00BYYW9G87
SymbolsAVCT, LSE:AVCT, AVCT.L, AVCT:LN, LON:AVCT, XLON:AVCT